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Abstract
Purpose To compare the impact of
sustained supplementation using different
macular carotenoid formulations on macular
pigment (MP) and visual function in early
age-related macular degeneration (AMD).
Patients and methods Sixty-seven subjects
with early AMD were randomly assigned to:
Group 1 (20mg per day lutein (L), 0.86mg
per day zeaxanthin (Z); Ultra Lutein), Group
2 (10mg per day meso-zeaxanthin (MZ), 10mg
per day L, 2mg per day Z; Macushield;
Macuhealth), Group 3 (17mg per day MZ,
3mg per day L, 2 mg per day Z). MP was
measured using customised heterochromatic
flicker photometry and visual function was
assessed by measuring contrast sensitivity
(CS) and best-corrected visual acuity (BCVA).
AMD was graded using the Wisconsin Age-
Related Maculopathy Grading System
(AREDS 11-step severity scale).
Results At 3 years, a significant increase in
MP from baseline was observed in all
groups at each eccentricity (Po0.05), except
at 1.75° in Group 1 (P= 0.160). Between 24
and 36 months, significant increases in MP at
each eccentricity were seen in Group 3
(Po0.05 for all), and at 0.50° in Group 2
(Po0.05), whereas no significant increases
were seen in Group 1 (P40.05 for all). At
36 months, compared with baseline, the
following significant improvements (Po0.05)
in CS were observed: Group 2—1.2, 6, and
9.6 cycles per degree (c.p.d.); Group 1—
15.15 c.p.d.; and Group 3—6, 9.6, and 15.15 c.p.
d. No significant changes in BCVA, or
progression to advanced AMD, were
observed.
Conclusion In early AMD, MP can be
augmented with a variety of supplements,
although the inclusion of MZ may confer
benefits in terms of panprofile augmentation
and in terms of CS enhancement.
Eye advance online publication, 15 May 2015;
doi:10.1038/eye.2015.64
Introduction
Age-related macular degeneration (AMD) is
characterised by a spectrum of degenerative
changes at the macula, which include drusen
and/or hyper-/hypopigmentary changes (known
as early AMD), atrophic changes (geographic
atrophy, GA, a form of advanced AMD), and
choroidal neovascularisation (neovascular or ‘wet
AMD’, another form of advanced AMD).1
Macular pigment (MP) is a yellow pigment
located in the macular region of the human
retina, and is composed of lutein (L), zeaxanthin
(Z), and meso-zeaxanthin (MZ).2 MP filters short-
wavelength blue light (and therefore limits
photooxidative damage passively) and its
constituent carotenoids act as antioxidants by
neutralizing free radicals.3,4
In the current study, known as the Meso-
zeaxanthin Ocular Supplementation Trial
(MOST) AMD study, we compared the effect
of sustained supplementation with some or all
of MP’s constituent carotenoids on visual
function, and evaluated the impact of such
supplementation on vision and disease
progression. Observations that MZ, the
dominant carotenoid in the epicentre of the MP’s
spatial profile, may offer advantages in terms of
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in terms of enhancement of visual function6 prompted
this investigation. The 8-week7 and 12-month8 reports
of the MOST AMD study have been published. In the
current study, we present new data on a 3-year follow-up
of subjects in the MOST AMD study. Of note, this is the
first study to monitor MP, visual function, and AMD
status in response to supplementation with all three
macular carotenoids in patients with early AMD, over a
36-month period.
Materials and methods
The design and methodology of the MOST AMD study
has been reported previously.8 In brief, MOST AMD is
a single-blind, randomised controlled clinical trial.
Clinical assessments were carried out at the Institute of
Eye Surgery (http://www.ioes.ie/), Waterford, Ireland.
Before study enrolment, an eligibility screening visit was
conducted by an ophthalmologist with a special interest
in retinal disease (SB). The eligibility criteria included
early AMD (one to eight on AREDS 11-step severity scale9
in at least one eye (the study eye), confirmed by the
Ocular Epidemilogy Reading Center at the University of
Wisconsin, Madison, WI, USA); best-corrected visual
acuity (BCVA) ≥ 6/12 in the study eye; and no other
ocular pathology.
Subjects were randomly assigned to one of three
parallel groups: Group 1—20mg L, 0.86mg Z (Ultra
Lutein supplied by Natural Organics, Inc., Melville, NY,
USA); Group 2—10mg MZ, 10mg L, 2mg Z (Macushield
(Macuvision Europe Limited, Solihull, UK)/Macuhealth
LMZ3 (MacuHealth LLC, Birmingham, MI, USA)); Group
3—17mg MZ, 3mg L, 2mg Z (supplied by Industrial
Organica, Monterrey, Mexico (not commercially
available)). The above treatment groups (formulations)
were selected to be comparable total concentrations of
macular carotenoids (ie 22mg). Of note, however,
discrepancies between label claim and measured values of
the supplements used in this trial have been reported
previously, and in particular, the finding that the Group 1
supplement contained small amounts of MZ
(0.30mg).10,11 This has implications for the findings
presented below.
The supplements were prepared in a soft gel capsule.
Subjects were instructed to take one capsule daily with
a meal. All study supplements were indistinguishable in
terms of external appearance, and were packaged in
identical containers. Study visits were conducted
at baseline, 12 months, 24 months, and 36 months.
Ethics
Ethics approval was granted by the Waterford Regional
Hospital Ethics Committee. Written and informed consent
was obtained from each subject before study enrolment.
The tenets of the Declaration of Helsinki were adhered to
in all study procedures.
Outcome measures
The primary outcome measure was change in MP as
measured by customized heterochromatic flicker
photometry (cHFP) at 36 months. Secondary outcome
measures included BCVA, letter contrast sensitivity (CS),
serum concentrations of macular carotenoids, and grade
of AMD.
Study procedures
MP measurement MP was measured using the Macular
Densitometer (Macular Metrics, Corp., Providence, RI,
USA) at 0.25°, 0.5°, 1.0°, and 1.75° retinal eccentricity,
with a reference point at 7°.12
Serum L, Z, and MZ analysis Serum L, Z, and MZ were
quantified by high-performance liquid chromatography
using methodology described previously.7,13
Visual acuity BCVA was measured using the Early
Treatment Diabetic Retinopathy Study (ETDRS)
logarithm of the minimum angle of resolution (LogMAR)
chart (Test Chart 2000 PRO; Thomson Software Solutions,
Hatfield, Hertfordshire, UK) viewed at 4m.
Letter CS Letter CS was assessed using the LogMAR
ETDRS (Test Chart 2000 PRO; Thomson Software
Solutions) chart at five different spatial frequencies (1.2, 2.4,
6.0, 9.6, and 15.15 c.p.d., respectively) viewed at 4m.
Retinal photography and AMD grading
Following prior pupillary dilation (0.5% proxymetacaine
hydrochloride, 2.5% phenylephrine hydrochloride, and
1% tropicamide), 45° stereoscopic color fundus
photographs were taken in three retinal photographic
fields (optic disc, macula, temporal to macula) using a
Zeiss Visucam 200 (Carl Zeiss Meditec AG, Jena,
Germany). Photographs were transferred to the Ocular
Epidemiology Reading Center at the University of
Wisconsin via an encrypted system. Photographs were
graded in a masked manner using a modified version
of the Wisconsin Age-Related Maculopathy Grading
System14,15 and adhered to the AREDS 11-step severity
scale.9
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One eye (the study eye) of each subject comprised the unit
of analysis. Statistical analysis was performed using IBM
SPSS Statistics for Windows, version 21.0 (IBM, Armonk,
NY, USA). To compare the effects of the three
supplements (on each outcome measure, over time),
we used repeated-measures analysis of variance, and
contingency table analysis, as appropriate. Cognisant that
this exploratory study would likely have insufficient
power for such analyses, however, we did some
additional analyses. In fact, and beyond the previously
reported 12-month data,8 we decided upon two strands of
analysis: (a) between supplement group analysis over
time: despite the small sample sizes, supplement groups
were compared with each other, for changes in each
outcome variable over the 3 years of the study. For
interval outcome variables (MP, serum carotenoids,
BCVA, CS), the method of analysis was repeated-
measures analysis of variance, with time as a within-
subjects factor and supplement as a between-subjects
factor; we used the Greenhouse–Geisser correction for
lack of sphericity. Post hoc analysis, with Bonferroni
adjustment for multiple testing, was used where
appropriate. For categorical outcome variables (AMD
grade), we used contingency table analysis to compare
supplements; (b) within-supplement group changes in
each outcome variable, over the 3 years of the study.
We used paired t-tests analysis here.
Tests of significance, for all t-test analyses, were two-
tailed, and the 5% level of significance was used
throughout. With the exception of post hoc analyses for the
repeated-measures analysis of variance, we did not
correct for multiple tests.
Results
Sixty-seven subjects were enrolled at baseline, with 47
subjects completing the final study visit at 36 months.
Only those subjects who completed each study visit were
included in analysis. Therefore, if a subject attended
his/her 12- or 24-month visit, but did not complete the
36-month visit, he/she was not included in the analysis.
Where a subject did complete a study visit, but where
a variable was not measured or recorded, that subject was
also excluded from all analyses relating to that variable.
Exclusions occurred only in the MP and CS analysis
because data were not available at all study visits (MP
analysis: 5 subjects; CS analysis: 6 subjects). We have also
included the sample size in all tables for clarity.
Baseline characteristics (eg age, gender, smoking
status, education) of participants in intervention groups
have been described previously, and the intervention
groups were statistically comparable in terms of these
variables.8
MP and its constituent carotenoids in serum
Macular pigment
(a) Comparing supplement groups In the repeated-
measures analysis of change in MP (at 0.25°, 0.5°, 1.0°,
and 1.75°), the within-subjects Time× Supplement
interaction effect was not significant (P= 0.759, 0.726,
0.703, 0.110, respectively, using the Greenhouse–Geisser
adjustment for lack of sphericity). Thus, the effect (on MP
levels) over time, at any eccentricity, does not differ
significantly between supplement groups. The boxplots in
Figure 1 graphically illustrate these findings.
(b) Within-supplement group analyses of MP are given
in Table 1.
Serum concentrations of lutein
(a) Comparing supplement groups In the repeated-
measures analysis of change in serum L, the within-
subjects Time× Supplement interaction effect was
significant (P= 0.029, using the Greenhouse–Geisser
adjustment for lack of sphericity). Thus, the effect (on
serum L levels) over time differs significantly between the
supplements used. Post hoc analysis indicates that
increases in serum L over time in groups 1 and 2 are
comparable (P= 1, after Bonferroni adjustment for
multiple testing), and each of these groups exhibit
significantly greater increases than group 3 (P= 0.029 and
P= 0.004, respectively, after Bonferroni adjustment for
multiple testing). The boxplots in Figure 2a graphically
illustrate these findings.
(b) Within-supplement group analyses of serum L are
given in Table 2.
Serum concentrations of MZ
(a) Comparing supplement groups In the repeated-
measures analysis of change in serum MZ, the within-
subjects Time× Supplement interaction effect was
significant (P= 0.011, using the Greenhouse–Geisser
adjustment for lack of sphericity). Thus, the effect over
time (on serum levels of MZ) differs significantly between
the supplement groups. Post hoc analysis indicates that
increases in MZ over time in Groups 2 and 3 are
comparable (P= 1, after Bonferroni adjustment for
multiple testing), and each of these groups exhibits
significantly greater increases than Group 1 (P= 0.001 for
both, after Bonferroni adjustment for multiple testing).
The boxplots in Figure 2b graphically illustrate these
findings.
(b) Within-supplement group analyses of serumMZ are
given in Table 2.
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Serum concentrations of zeaxanthin
(a) Comparing supplement groups In the repeated-
measures analysis of change in serum Z, the within-
subjects Time× Supplement interaction effect was not
significant (P= 0.081, using the Greenhouse–Geisser
adjustment for lack of sphericity). Thus, the effect over
time does not differ significantly between the
supplements. The boxplots in Figure 2c graphically
illustrate these findings.
(b) Within-supplement group analyses of serum Z are
given in Table 2.
Changes in visual function
(a) Comparing supplement groups There were no
significant Time× Supplement interaction effects for any
vision-related outcome measures (BCVA, letter CS at any
spatial frequency), indicating that the observed effects
over time in terms of these variables (see below) did not
differ between intervention groups.
Best-corrected visual acuity
Within-supplement group analysis There were no
significant within-supplement changes in BCVA (P40.05,
for all), with the exception of a statistically significant
improvement in Group 3 between 12 and 24 months.
Contrast sensitivity
Within-supplement group analysis of CS are given in
Table 3. At 36 months, compared with baseline, the
following significant improvements (Po0.05) in CS were
observed: Group 2—1.2, 6, and 9.6 c.p.d.; Group
1—15.15 c.p.d.; Group 3—6, 9.6, and 15.15 c.p.d.
Figure 1 Macular pigment response at different retinal eccentricities over the course of the MOST AMD study. Boxplots representing
macular pigment optical density at four time points (baseline, 12 months, 24 months, and 36 months) for each intervention group: Group
1—20mg L and 0.86mg Z; Group 2—10mg MZ, 10mg L, and 2mg Z; Group 3—17mg MZ, 3mg L, and 2mg Z Macular pigment was
measured at 0.25° (a), 0.5° (b), 1.0° (c), and 1.75° (d) eccentricity using cHFP. 0-G1, Baseline Group 1; 12-G1, 12 months Group 1; 24-G1,
24 months Group 1; 36-G1, 36 months Group 1; 0-G2, Baseline Group 2; 12-G2, 12 months Group 2; 24-G2, 24 months Group 2; 36-G2,
36 months Group 2; 0-G3, Baseline Group 3; 12-G3, 12 months Group 3; 24-G3, 24 months Group 3; 36-G3, 36 months Group 3. MPOD,
macular pigment optical density.
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Changes in grade of AMD
Because of the limited number of subjects in this study,
we collapsed adjacent grades of AMD, as follows: AREDS
grades 1–3 (representing eyes at low risk of progression to
advanced AMD), and AREDS grades 4–8 (representing
eyes at high risk of progression to advanced AMD).
In terms of this collapsed and simplified classification,
intervention groups were statistically similar in terms of
baseline findings (P= 0.44, χ2 test). Using this simplified
and modified system, no study eye in any intervention
group progressed from low risk to high risk of
progression to advanced AMD over the course of the
study period, and no study eye regressed from high risk
to low risk of progression to advanced AMD in any
intervention group, and finally, no subject progressed to
advanced AMD (AREDS grades 9–11) over the study
period. Given that findings were identical for all three
intervention groups, there was no need for statistical
investigation of differences between intervention groups
in terms of changes in risk for progression to
advanced AMD.
We also investigated clinically meaningful change in
AMD grade along the AREDS 11-step scale, defined as
a change of at least two steps along this scale. Thus, an
increase of two steps between baseline and final visit at
36 months was considered clinically meaningful disease
progression and a decrease of two steps was considered
a clinically meaningful disease regression. On this basis,
there was no clinically meaningful change in AMD grade
Figure 2 Serum response of L, MZ, and Z over the course of the MOST AMD study. Boxplots representing serum concentrations of L
(a), MZ (b), and zeaxanthin (c) at four time points (baseline, 12 months, 24 months, and 36 months) for each intervention group: Group 1
—20mg L and 0.86mg Z; Group 2—10mg MZ, 10mg L, and 2mg Z; Group 3—17mg MZ, 3mg L, and 2mg Z. Serum macular
carotenoids were analysed by HPLC and expressed as μmol/L; 0-G1, Baseline Group 1; 12-G1, 12 months Group 1; 24-G1, 24 months
Group 1; 36-G1, 36 months Group 1; 0-G2, Baseline Group 2; 12-G2, 12 months Group 2; 24-G2, 24 months Group 2; 36-G2, 36 months
Group 2; 0-G3, Baseline Group 3; 12-G3, 12 months Group 3; 24-G3, 24 months Group 3; 36-G3, 36 months Group 3.
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in 43 (93%) study eyes, whereas 3 (7%) study eyes (one
subject in Group 1 and two subjects in Group 3) exhibited
a clinically meaningful progression along the AREDS
11-step scale, and these observed changes were not
statistically different between intervention groups
(P= 0.29, Fisher’s exact test).
Discussion
The present study reports on the impact of sustained
supplementation with different carotenoid formulations
on serum concentrations of MP’s constituent carotenoids,
MP, visual function (BCVA and letter CS), and disease
progression in subjects with early AMD.
The strengths of this study include: (1) it is a
randomized clinical trial comparing three different
formulations containing some or all of MP’s constituent
carotenoids, with a follow-up of 3 years; (2) MP was
measured using a validated technique at regular intervals
throughout the study period; (3) assessment of visual
function was not restricted to BCVA, and included CS;
(4) assessment of AMD morphology was performed by an
accredited reading centre in a masked manner.
Serum response to supplementation reflected the
carotenoid content of the supplement used. For example,
serum L exhibited an increase in all three
supplementation groups, but to a greater extent in Groups
1 and 2, where intake of L was at least three times the
typical dietary intake of this carotenoid.16,17 Similarly,
a significant rise in serum Z was noted following
supplementation, but that was comparable across
supplement groups, reflecting similar concentrations of
this carotenoid in each of the three formulations tested.
Finally, serum MZ response is noteworthy for several
reasons. First, MZ was detected in the serum of patients
supplemented with a formulation with no declared MZ
content. However, we have shown that MZ is indeed
present in commercially available formulations
containing L, including Ultra Lutein, the Group 1
supplement used in this study.10 Finally, it is also worth
noting that serum L and serum Z responses were
unaffected by the presence of substantial concentrations
of MZ (10mg or more) in the formulation used, thereby
allaying previously expressed concerns that the inclusion
of MZ in a supplement may adversely impact upon the
circulating bioavailability of the other two macular
carotenoids.
MP increased significantly in all groups at each
eccentricity (with the exception of Group 1 at 1.75°) at
3 years. It is surprising to see that MP did not increase
at 1.75° in Group 1, given that L is the dominant
carotenoid at this locus, and this seemingly
counterintuitive observation might be because subjects in
Group 1 were bioconverting L to MZ at the macula.18,19
Consistent with this hypothesis, only groups that received
supplemental MZ exhibited significant augmentation of
MP across the spatial profile of this pigment.
In terms of MP increase over the course of the study,
it was observed that MP continues to increase further and
significantly in the third year of supplementation
(but only in groups supplemented with meaningful
concentrations of MZ) following a relative plateau in the
second year of supplementation. Indeed, MP did not
increase significantly between 12 and 24 months in any
intervention group, at any eccentricity. Although the
exact mechanism of macular carotenoid uptake has not
been fully elucidated, it is plausible that there are several
mediators (eg binding proteins, enzymes) that influence
the capture, accumulation, and stabilisation of these
carotenoids at the macula,20 but further research is
needed to understand these mechanisms.
There was no significant change in BCVA over the
course of the present study, other than a transient
improvement between 12 and 24 months in Group 3.
Murray et al21 reported the impact of supplemental L on
MP and visual acuity in patients with early AMD in
a randomised, double-blind, placebo-controlled,
multicentre 12-month trial. At the end of their study, there
was no change in BCVA in the L group, whereas BCVA
in the placebo group had deteriorated significantly.21
In the present study, there was a nonsignificant increase
in BCVA in all intervention groups, consistent with the
view that BCVA stabilised over the 3-year period of the
study in this cohort of patients with early AMD. The
CARMA trial, a randomised controlled trial of L, Z, and
coantioxidants vs placebo, reported no significant change
in BCVA at 1 year, although there was a demonstrable
benefit in terms of differential BCVA between
intervention and placebo groups at 3 years.22,23 Of note,
visual acuity, which is a measure of the spatial resolving
power of the visual system and remains the most
commonly used measure of vision in clinical practice,24
is probably not sensitive enough to detect subtle but
important changes in visual function experienced when
monitoring subjects with early AMD.25
CS measures the threshold between visible and
invisible at a given spatial frequency, and could be loosely
described as ‘faintness appreciation’26 and is a better tool
than BCVA for assessing visual function in early AMD.25
In Group 2 (a supplement with a formulation containing
all three of MP’s constituent carotenoids), there was a
statistically significant improvement in CS at the lowest
spatial frequency (2.4 c.p.d.), whereas this was not
observed for Groups 1 and 3. At the highest spatial
frequency (15.15 c.p.d.), letter CS improved in Groups 1
and 3 at 36 months, but not in Group 2. At intermediate
spatial frequencies (6 and 9.6 c.p.d.), however, only
supplementation with formulations containing
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appreciable amounts of MZ (Groups 2 and 3) resulted in a
significant improvement in letter CS. Although some, but
not all, previous studies have reported improvements in
CS following supplementation with macular carotenoids
in subjects with early AMD, our results suggest that those
studies that failed to report an improvement in CS may
be explained, at least in part, by a lack of MZ in the
supplement formulation used.23,27 Finally, an important
and novel finding of the current study rests on the
observation that further and significant improvements
in CS are experienced beyond 24 months of
supplementation with MP’s constituent carotenoids,
suggesting that sustained supplementation is indeed
necessary to exert a beneficial effect on visual function.
With respect to AMD, only three study eyes exhibited
clinically meaningful disease progression (1 subject from
Group 1 and 2 subjects from Group 3), and no study eye
progressed to advanced AMD over the 3-year study
period. This study is not adequately powered or designed
to make meaningful comment on AMD progression.
The current study compared the impact of
supplementation with different carotenoid formulations
on visual function, and our findings suggest that a
formulation containing MZ yields benefits in terms of MP
augmentation and in terms of CS enhancement. Further,
sustained supplementation appears necessary, for at least
3 years, if MP is to be augmented maximally and CS is to
be optimised over that period of time. Of note, modest
visual benefits were observed in the current study. Future
clinical trials should examine the impact of
supplementation with formulations containing MZ and
Z at similar doses. The Central Retinal Enrichment
Supplementation Trial (CREST), currently underway, will
also add to our understanding of the role of the macular
carotenoids, including MZ, on vision in healthy and
diseased eyes.28
Limitations of the MOST AMD study include its small
numbers and the fact that it is a single blind clinical trial
with no placebo arm. With respect to the use of placebo in
the current study, we believe that the findings arising
from the secondary analysis of the AREDS2 may render
the use of placebo in patients with early (including
intermediate) AMD ethically questionable.29,30 Of note,
the term early AMD in this study includes patients with
intermediate AMD (as defined by AREDS). However, the
absence of placebo may render it difficult to demonstrate
clinical efficacy of the different carotenoid formulations
used in this study and our results should be interpreted
with full appreciation of this limitation. We used the
single-blind design because the current study was the first
clinical trial to compare the impact of supplementation
with three different carotenoid formulations (including
MZ) on visual function in subjects with early AMD and
therefore we wanted to monitor more closely the effects of
the three carotenoid formulations in terms of response
among these subjects. Statistically, this exploratory study
was underpowered for a direct comparison of the three
supplements. Differences in effects between supplements
were, in general, likely to be small, meaning that
impractically large numbers of subjects would have been
required to obtain statistically significant results.
In conclusion, we report that the inclusion of MZ in
a supplement formulation seems to confer benefits in
terms of MP augmentation and in terms of enhanced CS
in subjects with early AMD. An important and novel
finding rests on the observation that sustained
supplementation with the macular carotenoids seems
necessary to maximally augment MP and to optimise
CS over a 3-year period in patients with early AMD.
Summary
What was known before
K MP augmentation can be achieved with a variety of
supplements.
K The inclusion of MZ in a formulation appears to confer
greater benefits in terms of visual function and
augmentation of MP in subjects with early AMD at
12 months.
What this study adds
K Sustained supplementation in subjects with early AMD
results in further augmentation of MP following 2 years of
continuous supplementation, and confers visual benefit in
these patients in terms of CS.
K The inclusion of MZ in a formulation appears to be
important if increases in MP, and consequential
improvements in vision, are to be maximised in subjects
with early AMD receiving supplements.
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